Cargando…
Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data
BACKGROUND: Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580438/ https://www.ncbi.nlm.nih.gov/pubmed/28863782 http://dx.doi.org/10.1186/s12885-017-3609-6 |
_version_ | 1783260900206051328 |
---|---|
author | Yu, Rentao Tan, Zhaoxia Xiang, Xiaomei Dan, Yunjie Deng, Guohong |
author_facet | Yu, Rentao Tan, Zhaoxia Xiang, Xiaomei Dan, Yunjie Deng, Guohong |
author_sort | Yu, Rentao |
collection | PubMed |
description | BACKGROUND: Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical data has barely been studied. METHODS: A total of 14,861 samples were tested in Southwest Hospital in over 2 years’ time. Among them, 4073 samples were PIVKA-II positive. Finally, a total of 2070 patients with at least two image examinations were enrolled in this study. Levels of AFP and PIVKA-II were measured by chemiluminescence enzyme immunoassay (CLEIA) and chemiluminescent microparticle Immunoassay (CMIA), respectively. RESULTS: A total of 1016 patients with HCC were detected by PIVKA-II in a real-world application. In all these cases, 88.7% cases primarily occurred and patients with advanced HCC covered 61.3%. Levels of PIVKA-II were significantly higher in advanced group (4650.0 mAU/ml, 667.0–33,438.0 mAU/ml) than early-stage group (104.5 mAU/ml, 61.0–348.8 mAU/ml; P < 0.001). Levels of PIVKA-II elevated significantly in recurrence and residual group than recovery group (P < 0.001). A total of 1054 PIVKA-II positive patients were non-HCC cases. Among them, cirrhosis took the largest part (46.3%), followed by hepatitis (20.6%) and benign nodules (15.3%). High-levels of PIVKA-II in at-risk patients is an indicator of HCC development in two-year time. CONCLUSIONS: Our data showed that PIVKA-II effectively increases the detection rate of HCC was a valid complement to AFP and image examination in HCC surveillance. |
format | Online Article Text |
id | pubmed-5580438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55804382017-09-07 Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data Yu, Rentao Tan, Zhaoxia Xiang, Xiaomei Dan, Yunjie Deng, Guohong BMC Cancer Research Article BACKGROUND: Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical data has barely been studied. METHODS: A total of 14,861 samples were tested in Southwest Hospital in over 2 years’ time. Among them, 4073 samples were PIVKA-II positive. Finally, a total of 2070 patients with at least two image examinations were enrolled in this study. Levels of AFP and PIVKA-II were measured by chemiluminescence enzyme immunoassay (CLEIA) and chemiluminescent microparticle Immunoassay (CMIA), respectively. RESULTS: A total of 1016 patients with HCC were detected by PIVKA-II in a real-world application. In all these cases, 88.7% cases primarily occurred and patients with advanced HCC covered 61.3%. Levels of PIVKA-II were significantly higher in advanced group (4650.0 mAU/ml, 667.0–33,438.0 mAU/ml) than early-stage group (104.5 mAU/ml, 61.0–348.8 mAU/ml; P < 0.001). Levels of PIVKA-II elevated significantly in recurrence and residual group than recovery group (P < 0.001). A total of 1054 PIVKA-II positive patients were non-HCC cases. Among them, cirrhosis took the largest part (46.3%), followed by hepatitis (20.6%) and benign nodules (15.3%). High-levels of PIVKA-II in at-risk patients is an indicator of HCC development in two-year time. CONCLUSIONS: Our data showed that PIVKA-II effectively increases the detection rate of HCC was a valid complement to AFP and image examination in HCC surveillance. BioMed Central 2017-09-01 /pmc/articles/PMC5580438/ /pubmed/28863782 http://dx.doi.org/10.1186/s12885-017-3609-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Yu, Rentao Tan, Zhaoxia Xiang, Xiaomei Dan, Yunjie Deng, Guohong Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data |
title | Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data |
title_full | Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data |
title_fullStr | Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data |
title_full_unstemmed | Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data |
title_short | Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data |
title_sort | effectiveness of pivka-ii in the detection of hepatocellular carcinoma based on real-world clinical data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580438/ https://www.ncbi.nlm.nih.gov/pubmed/28863782 http://dx.doi.org/10.1186/s12885-017-3609-6 |
work_keys_str_mv | AT yurentao effectivenessofpivkaiiinthedetectionofhepatocellularcarcinomabasedonrealworldclinicaldata AT tanzhaoxia effectivenessofpivkaiiinthedetectionofhepatocellularcarcinomabasedonrealworldclinicaldata AT xiangxiaomei effectivenessofpivkaiiinthedetectionofhepatocellularcarcinomabasedonrealworldclinicaldata AT danyunjie effectivenessofpivkaiiinthedetectionofhepatocellularcarcinomabasedonrealworldclinicaldata AT dengguohong effectivenessofpivkaiiinthedetectionofhepatocellularcarcinomabasedonrealworldclinicaldata |